Acumen Research and Consulting recently published report titled “Blood Purification Devices Market Share, Analysis Report and Region Forecast, 2022 - 2030”
LOS ANGELES, Sept. 01, 2022 (GLOBE NEWSWIRE) -- LOS ANGELES, September 01, 2022 (GLOBE NEWSWIRE) – The Global Blood Purification Devices Market is expected to grow at a CAGR of around 3.8% from 2022 to 2030 and expected to reach the market value of around USD 6,280 Million by 2030.
Blood Purification Devices Market Report Key Highlights
• Global blood purification devices market size was USD 4,534 million in 2021 and is expected to grow at CAGR of 3.8% from 2022 to 2030
• North America blood purification devices market is expected to lead with more than 45% market share
• Asia-Pacific blood purification devices market is expected to grow at fastest CAGR during the forecast period from 2022 to 2030
• Among types, portable blood purification devices occupied more than 60% of the total market share
• According to the WHO, CKD affects more than 10% of the population in the world
Request For Free Sample Report @
https://www.acumenresearchandconsulting.com/request-sample/2427
Blood Purification Devices Market Size 2021
Blood Purification Devices Market Forecast 2030
Blood Purification Devices Market CAGR During 2022 - 2030
Blood Purification Devices Market Analysis Period
Blood Purification Devices Market Base Year
Blood Purification Devices Market Forecast Data
By Type, By Application, By End-use And By Geography
Blood Purification Devices Market Regional Scope
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Accel Diagnostics, Aethlon Medical, Cerus Company, Circle Biologics, CytoSorbents, Jafron, Medtronic, NxStage Medical, Spectral Medical, Stellarray, Toray Medica, and among others.
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
COVID-19 Impact on the Global Blood Purification Devices Market Revenue
The innovative COVID-19 pandemic is projected to have a significant impact on the global blood purifying equipment market's overall growth in 2020. The US Food and Drug Administration announced in July 2021 that blood purifying devices could be beneficial in treating certain individuals with confirmed COVID-19 by reducing cytokines, infections, and other inflammatory mediators. Baxter India, a subsidiary of Baxter International, has received approval from India's Central Drugs Standard Control Organization (CDSCO) for its blood purification filter oXiris for the diagnosis of COVID-19 patients.
Blood Purification Devices Market Dynamics
Market Driver: Commercialization of Products Fuels the Global Blood Purification Devices Market Value
Rising incidences of chronic kidney disease (CKD) will enhance the commercialization of blood purification devices in the worldwide market. According to the Center for Disease Control and Prevention, CKD is more prevalent in people aged 65 years or older which constitute around (38%) than in people aged 45-64 years (13%) or 18-44 years (7%). Additionally, National Chronic Disease Fact Sheet highlights that around 15% of adults are estimated to suffer from CKD in the US alone. This scenario proves beneficial for the blood purification devices industry growth as it raises the demand for globally.
Market Opportunities: Technological Advancements Offers Lucrative Benefits for the Global Blood Purification Device Market Share
Technological advancements coupled with innovations positively influence the market. For records, prominent players such as NxStage and Jafron have a wide product portfolio of blood purification devices that focus on reducing the mortality rate in patients suffering from acute kidney failure. In May 2017, NxStage Medical, Inc. announced next generation hemodialysis system that has received FDA clearance. The newly launched product has specialized features and capabilities that involve a new touch screen user interface and integrated blood pressure monitor designed and assists for easy use for patients performing home hemodialysis.
Check the detailed table of contents of the report @
https://www.acumenresearchandconsulting.com/table-of-content/blood-purification-devices-market
Blood Purification Devices Market Segmentation
The blood purification devices market is segmented based on type, application, and end-user. By type, the market is bifurcated into portable and stationary. According to our blood purification devices market forecast, the portable segment acquired the largest market share from 2022 to 2030.
By application, the market is categorized as continuous blood purification, hemoperfusion, and hemodialysis. Based on our blood purification devices industry analysis, the continuous blood purification sub-segment is expected to lead the market with the utmost shares in 2021 and is likely to do so in the coming years.
By end-user, the market is segregated into hospitals, clinics, and others. Based on our analysis, the hospital sub-segment acquired significant blood purification devices market share in 2021.
Blood Purification Devices Market Regional Outlook
North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa are the regional categorizations of the blood purification devices market industry.
North America will dominate the global blood purification devices regional market forecast period. Fast product approvals, high government involvement during the COVID-19 pandemic to support the patient population with different product offerings, and growing demand from the geriatric population enhance the growth of blood purification devices for the North American regional market.
In April 2020, US FDA approved a blood purification device to tackle COVID-19 patients. The new system approved can be utilized among patients who are 18 years or older and have been admitted to the ICU. The product plays a vital role in support in favor of patients experiencing or will experience respiratory failure.
On the other hand, Asia-Pacific will gain a significant pace in the coming years for the blood purification device market. The Asia-Pacific blood purification device market will grow tremendously through rising adoption levels for several new products, new medical diagnostics, and treatment procedures. Additionally, with the high population base in the Asia-Pacific region suffering from kidney-related disorders, and cardiac dysfunction, technological advancements in blood collection tubes aligned with filtration techniques act positively for the regional market growth.
Buy this premium research report –
https://www.acumenresearchandconsulting.com/buy-now/0/2427
Blood Purification Devices Market Players
Some of the leading blood purification devices companies are Accel Diagnostics, Aethlon Medical, Cerus Company, Circle Biologics, CytoSorbents, Jafron, Medtronic, NxStage Medical, Spectral Medical, Stellarray, Toray Medical, and others.
Some of the key observations regarding the blood purification devices industry include
• In March 2020, Cerus Company announced the approval of its new product namely, Intercept plasma with an alternative plastic disposable kit. The newly launched product is designed such that the Intercept blood system is best suited to reducing pathogens, viruses, bacteria, protozoa, and contaminating donor leukocytes in plasma components. The new product once used assists in reducing the risk of transfusion-transmitted infections.
• In December 2020, Medtronic announced the launching of a new product name, the Carpediem cardio-renal pediatric dialysis emergency machine in the U.S. The product is highly specialized for treating acute kidney injury or fluid overloaded patients requiring hemodialysis or hemofiltration therapy. The first Carpediem machine, intended to provide continuous renal replacement therapy (CRRT) is offered to patients between 2.5 to 10 kg and was successfully installed and is currently used at Cincinnati Children’s Hospital Medical Center.
• In February 2020, Baxter announced a partnership with Spectral Medical for the distribution of TORAYMYXIN™ PMX-20R (PMX), a hemoperfusion filter, and the Endotoxin Activity Assay™ (EAA), an on-market companion diagnostic tool that aids in the risk assessment of ICU patients for progression to severe sepsis.
Questions Answered By This Report
What was the market size of Blood Purification Devices Market in 2021?
What will be the CAGR of Blood Purification Devices Market during the forecast period from 2022 to 2030?
Who are the major players in Global Food Waste Management Market?
Which region held the largest share in Blood Purification Devices Market in 2021?
What are the key market drivers of Food Waste Management Market?
Who is the largest end user Food Waste Management Market?
What will be the Blood Purification Devices Market value in 2030?
Browse More Research Topic on Healthcare Related:
The Worldwide Medical Pendant Market accounted for USD 466 Million in 2021 and is expected to hit USD 830 Million by 2030, with a significant CAGR of 6.7% from 2022 to 2030.
The Global Super Absorbent Dressings Market accounted for USD 95 Million in 2021 and is expected to reach USD 141 Million by 2030 with a considerable CAGR of 4.5% during the forecast timeframe of 2022 to 2030.
The Worldwide Colposcopy Market accounted for USD 455 Million in 2021 and is expected to hit USD 711 Million by 2030, with a significant CAGR of 5.3% from 2022 to 2030.
About Acumen Research and Consulting:
Acumen Research and Consulting is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.
For Latest Update Follow Us on Twitter and, LinkedIn
Long-time Real Money subscribers have come to learn I like to combine investment approaches. No one investment approach (fundamental, technical, quantitative) is perfect and better results can come from blending or combining different methods. The On-Balance-Volume (OBV) line has also moved sideways suggesting a balance between buyers and sellers.
Stéphane Bancel discusses the company’s latest Covid shot and prospects for using mRNA in seasonal flu vaccines and personalized treatments for cancer
Investors have lost patience with the slow-paced clinical trials of genetic therapies, and some are using the upbeat news to exit Intellia and peers.
Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. But CRISPR stocks sank.
Omeros Corp (NASDAQ: OMER) reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID Trial. The company said that in approximately half of the patients died in the narsoplimab group, and narsoplimab was not given or was prematurely stopped, with those patients dying 9 to 35 days later. Omeros adds that despite narso
A San Francisco-based immunology company that wants to help eradicate infectious disease globally has expanded its footprint in St. Louis, opening a new $41 million office within the Cortex innovation district. It says the new facility will be critical to advancing research to treat several infectious diseases, including Covid-19.
In that spirit, let's examine two healthcare stocks that seem to have the tools to provide solid returns over the long term: Eli Lilly (NYSE: LLY) and Teladoc Health (NYSE: TDOC). Eli Lilly seems to excel in both areas. Take one of the company's most recent approvals: Mounjaro, a therapy used to control blood glucose levels in patients with type 2 diabetes.
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
Gilead Sciences Inc (NASDAQ: GILD) announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury (remdesivir) for severe COVID-19. WHO continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization. The WHO conditional recommendation is mainly driven by the final results of the WHO-sponsored SOLIDARITY study, which showed a statistically significant 17% lowe
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2022.
Huntsman Corp is a manufacturer and marketer of chemical products for consumers and industrial customers - assorted polyurethanes, performance products, and adhesives. The trading volume has been active since February and the On-Balance-Volume (OBV) line has been in a downward trend since February telling us that sellers of this company have been more aggressive than buyers. The OBV line is stalled and beginning to weaken.
A labor shortage at a pharmaceutical company along with increased demand left Adderall on back-order at many pharmacies across the country.
Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.
Intellia Therapeutics said two of its experimental Crispr treatments produced positive results in early-stage trials.
J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.
Saudi Arabia and Russia, the de facto leaders of the OPEC+ oil producer group, see $100 a barrel as a fair price that the global economy can absorb, sources familiar with government thinking in the two countries told Reuters. The Organization of the Petroleum Exporting Countries, Russia and other allies, known as OPEC+, pumps more than 40% of the 100 million barrels per day of global output. OPEC+ does not explicitly state its preferred price level.
Indian billionaire Gautam Adani is now the world’s second richest person. The only person richer than him now is Tesla chief Elon Musk.
As the bear market emerged, even some of the healthiest companies saw their shares drop or stagnate. Shares of Axsome Therapeutics (NASDAQ: AXSM) have climbed 64% this year. Most of the gains came in recent weeks after the company's great news: It won U.S. regulatory approval for Auvelity, its drug for major depressive disorder (MDD).
Though the mining industry has been hit hard in recent years, this gold producer is going strong and continues to grow